eligibility_summary
Adults (≥18) with advanced: ovarian/fallopian/primary peritoneal or endometrial, lung adenocarcinoma, triple‑negative breast, pancreatic ductal, or pleural mesothelioma. Progression after prior therapy with no standard options, measurable/non‑measurable disease, ECOG 0–1, adequate organs, tumor tissue. Exclude prior FRα therapy, active CNS mets, unresolved >G1 AEs, recent therapy/radiation/major surgery, prior BMT, major cardiac/pulmonary/ocular disease, infection, TE/CVA, or pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05498597 tests AMT-151, an intravenously administered antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). Mechanism: a monoclonal antibody binds FRα on tumor cells, is internalized via FRα-mediated endocytosis, and releases an intracellular cytotoxic payload to kill cancer cells. Targeted cells/pathways: FRα-overexpressing epithelial tumor cells, folate-receptor–mediated internalization with downstream induction of tumor cell death. Tumor types include FRα-positive advanced solid tumors such as ovarian and endometrial cancers, lung adenocarcinoma, triple-negative breast cancer, PDAC, and mesothelioma.